In the news

Company Background

Parallel Bio unlocks the human body’s own power to cure disease. It developed the first platform that replicates the human immune system in a dish for drug discovery and development. It models human disease more realistically and accurately than animal testing—leading to the fastest path to treatments and cures that work for more people. Through its combination of immune organoids, machine learning and robotics, the platform represents the complexity of disease and the diversity of patients at population scale. Based in Cambridge, Mass., the company was founded in 2021 by two scientists responsible for creating the world’s first scalable human immune organoid.

• Headquarters: Cambridge, Massachusetts
• Year founded: 2021
• Investors: Refactor Capital, Breakout Ventures, Y Combinator, Jeff Dean, Gaingels, and more
• Media contact: press@parallel.bio